Final MATTERHORN Trial Results Show Durvalumab Improves Overall Survival in Resectable Gastric Cancer

Final overall survival analysis from the global, randomized Phase 3 MATTERHORN clinical trial, published in The Lancet, indicates that adding perioperative durvalumab to standard chemotherapy reduced the risk of death by 22% in patients with localized, resectable gastric or gastroesophageal junction cancer. This supports the new perioperative combination as a standard treatment option.